세계의 뎅기열 백신 시장 : 백신 유형별, 최종 사용자별, 연령층별, 백신 개발 단계별, 유통 채널별, 투여 경로별, 기술별, 환자 유형별 예측(2025-2030년)

The Dengue Vaccine Market was valued at USD 1.38 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 11.79%, to USD 3.02 billion by 2030.

The global dengue vaccine market is recognized for its critical role in combating dengue fever, a mosquito-borne tropical disease affecting millions annually. The scope encompasses both prophylactic and therapeutic solutions, addressing the urgent public health need to reduce dengue incidence and mortality. The necessity of the dengue vaccine is underscored by the increasing prevalence of the disease in tropical and subtropical regions, fueled by climate change, urbanization, and increased travel. Applications primarily involve immunization programs targeting adolescents and adults in endemic regions. End-use scope includes hospitals, clinics, and public health centers, with potential expansion into travel centers and tourist hubs.

Market growth is influenced by several factors, including rising awareness about mosquito-borne diseases, government initiatives for immunization, and advancements in vaccine technologies, such as live attenuated vaccines and recombinant vaccines. Opportunities lie in expanding vaccine coverage globally, stimulating demand across emerging markets in Southeast Asia, Latin America, and Africa. Developing multi-valent vaccines targeting various dengue virus serotypes offers a significant opportunity, as does exploring novel delivery systems, such as oral or transdermal routes, which can enhance compliance and accessibility.

Challenges include regulatory hurdles, particularly concerning safety and efficacy across diverse populations and serotypes, which can impede approval processes. Additionally, logistical issues in vaccine distribution and cold chain maintenance pose practical barriers. The relatively high cost of vaccines can limit access in low-income regions, necessitating scalable production and pricing strategies.

Innovative areas for research include developing vaccines with broader serotype coverage and longer immunity duration, utilizing cutting-edge platforms like mRNA and vector-based technologies. Moreover, exploring synergies with mosquito control initiatives and integrating vaccines into broader health strategies could ensure more comprehensive disease management. The nature of the market is dynamic, driven by technological progress and shifting epidemiological patterns, underscoring the need for continuous research and collaboration across sectors to achieve impactful health outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dengue Vaccine Market

The Dengue Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
  • Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
  • Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
  • Rising public awareness and education campaigns about the importance of dengue vaccination
• Market Restraints
  • High R&D and clinical trial costs
• Market Opportunities
  • Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
  • Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
  • Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
• Market Challenges
  • Logistical issues in vaccine delivery and vaccine hesitancy

Porter's Five Forces: A Strategic Tool for Navigating the Dengue Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dengue Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dengue Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dengue Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dengue Vaccine Market

A detailed market share analysis in the Dengue Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dengue Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dengue Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dengue Vaccine Market

A strategic analysis of the Dengue Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dengue Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, Bio Farma, Biological E. Limited, CSL Limited, CureVac AG, GeneOne Life Science, Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Medigen Vaccine Biologics Corp., Merck & Co., Inc., Panacea Biotec, PaxVax, Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Vabiotech.

Market Segmentation & Coverage

This research report categorizes the Dengue Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Vaccine Type, market is studied across DNA Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Subunit Vaccines.
• Based on End User, market is studied across Clinics, Government and Non-Government Organizations, Hospitals, and Research Institutes.
• Based on Age Group, market is studied across Adolescent, Adult, and Pediatric.
• Based on Vaccine Development Stage, market is studied across Clinical Trials, Phase I, Phase II, Phase III, and Pre-Clinical.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Route of Administration, market is studied across Injection, Nasal, and Oral.
• Based on Technology, market is studied across Conventional Vaccines and Next-Generation Vaccines. The Conventional Vaccines is further studied across Split Virus Vaccines and Whole Virus Vaccines. The Next-Generation Vaccines is further studied across Virus-Like Particles.
• Based on Patient Type, market is studied across Symptomatic.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
    • 5.1.1.2. Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
    • 5.1.1.3. Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
    • 5.1.1.4. Rising public awareness and education campaigns about the importance of dengue vaccination
  • 5.1.2. Restraints
    • 5.1.2.1. High R&D and clinical trial costs

• 5.1.3. Opportunities
  • 5.1.3.1. Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
  • 5.1.3.2. Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
  • 5.1.3.3. Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
• 5.1.4. Challenges
  • 5.1.4.1. Logistical issues in vaccine delivery and vaccine hesitancy

• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dengue Vaccine Market, by Vaccine Type

• 6.1. Introduction
• 6.2. DNA Vaccines
• 6.3. Inactivated Vaccines
• 6.4. Live Attenuated Vaccines
• 6.5. Recombinant Vaccines
• 6.6. Subunit Vaccines

7. Dengue Vaccine Market, by End User

• 7.1. Introduction
• 7.2. Clinics
• 7.3. Government and Non-Government Organizations
• 7.4. Hospitals
• 7.5. Research Institutes

8. Dengue Vaccine Market, by Age Group

• 8.1. Introduction
• 8.2. Adolescent
• 8.3. Adult
• 8.4. Pediatric

9. Dengue Vaccine Market, by Vaccine Development Stage

• 9.1. Introduction
• 9.2. Clinical Trials
• 9.3. Phase I
• 9.4. Phase II
• 9.5. Phase III
• 9.6. Pre-Clinical

10. Dengue Vaccine Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Dengue Vaccine Market, by Route of Administration

• 11.1. Introduction
• 11.2. Injection
• 11.3. Nasal
• 11.4. Oral

12. Dengue Vaccine Market, by Technology

• 12.1. Introduction
• 12.2. Conventional Vaccines
  • 12.2.1. Split Virus Vaccines
  • 12.2.2. Whole Virus Vaccines
• 12.3. Next-Generation Vaccines
  • 12.3.1. Virus-Like Particles

13. Dengue Vaccine Market, by Patient Type

• 13.1. Introduction
• 13.2. Symptomatic

14. Americas Dengue Vaccine Market

• 14.1. Introduction
• 14.2. Argentina
• 14.3. Brazil
• 14.4. Canada
• 14.5. Mexico
• 14.6. United States

15. Asia-Pacific Dengue Vaccine Market

• 15.1. Introduction
• 15.2. Australia
• 15.3. China
• 15.4. India
• 15.5. Indonesia
• 15.6. Japan
• 15.7. Malaysia
• 15.8. Philippines
• 15.9. Singapore
• 15.10. South Korea
• 15.11. Taiwan
• 15.12. Thailand
• 15.13. Vietnam

16. Europe, Middle East & Africa Dengue Vaccine Market

• 16.1. Introduction
• 16.2. Denmark
• 16.3. Egypt
• 16.4. Finland
• 16.5. France
• 16.6. Germany
• 16.7. Israel
• 16.8. Italy
• 16.9. Netherlands
• 16.10. Nigeria
• 16.11. Norway
• 16.12. Poland
• 16.13. Qatar
• 16.14. Russia
• 16.15. Saudi Arabia
• 16.16. South Africa
• 16.17. Spain
• 16.18. Sweden
• 16.19. Switzerland
• 16.20. Turkey
• 16.21. United Arab Emirates
• 16.22. United Kingdom

17. Competitive Landscape

• 17.1. Market Share Analysis, 2023
• 17.2. FPNV Positioning Matrix, 2023
• 17.3. Competitive Scenario Analysis
• 17.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca
• 2. Bharat Biotech
• 3. Bio Farma
• 4. Biological E. Limited
• 5. CSL Limited
• 6. CureVac AG
• 7. GeneOne Life Science, Inc.
• 8. GlaxoSmithKline plc
• 9. Inovio Pharmaceuticals, Inc.
• 10. Johnson & Johnson
• 11. Medigen Vaccine Biologics Corp.
• 12. Merck & Co., Inc.
• 13. Panacea Biotec
• 14. PaxVax, Inc.
• 15. Pfizer Inc.
• 16. Sanofi
• 17. Serum Institute of India Pvt. Ltd.
• 18. Sinovac Biotech Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Vabiotech